Skip to main content

Table 1 Clinical characteristics of the study cohort (n = 9)

From: Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer

Mean agea, years (range) 64.2 (51–74)
Gleason score at diagnosisb, n (%)
7 (3 + 4) 5 (55.6)
9 4 (44.4)
Metastatic sites, n (%)
Bone 9 (100)
Lymph node 2 (22.2)
Evidence of castration resistance at recruitment (cohort)c, n (%)
No (mPCa; cohort 1) 5 (55.6)
Yes (mCRPC; cohort 2) 4 (44.4)
Number of timepointsd, n (%)
4 2 (22.2)
5 2 (22.2)
6 5 (55.6)
Mean cfDNA concentratione, ng/ul (range) 5.08 (0.61–38)
Mean PSA levelse, ng/ml (range) 35.3 (0.1–352.1)
Therapies administeredf, n (%)
LHRH agonists/antagonists 8 (88.9)
Taxanes 9 (100)
AR-inhibitors 8 (88.9)
Radioisotopes 3 (33.3)
Mean follow-up timeg, months (range) 19.1 (13–21)
  1. AR androgen receptor, cfDNA cell-free DNA, LHRH Luteinizing hormone-releasing hormone, mPCa metastatic prostate cancer, mCRPC metastatic castration resistant prostate cancer, PSA prostate-specific antigen
  2. Other notes: aAge at time of recruitment
  3. bPrior to recruitment
  4. cCohort classification: Cohort 1—patient was on/starting androgen deprivation therapy at time of recruitment, and had no evidence of castration resistance; Cohort 2—patient had castration resistant disease at time of recruitment
  5. dTimepoint refers to number of cfDNA isolations available for study
  6. eAt any given timepoint
  7. fDuring follow-up in the iPROSPECT study
  8. gFollow-up time reflects last timepoint obtained for this analysis